secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-08-05T11:02:39+00:00
Accession:  0001171843-26-005223
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q2 revenue $218.3M, GAAP operating profit $98.5M; raises total revenue guidance
--------------------------------------------------------------------------------

- ORLADEYO net revenue $158.2M (+1% YoY); oral pellets shipping to pediatric patients began Aug 3.
- GAAP operating profit $98.5M; non-GAAP operating profit $113.2M; cash $354M.
- Raised FY2026 total revenue guidance to $690-715M; ORLADEYO guidance unchanged $625-645M.
- Completed enrollment in navenibart pivotal study (ALPHA-ORBIT); top-line data expected Q3 2027.
- Licensed navenibart European rights to Neopharmed Gentili for $70M upfront plus milestones/royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/0001171843-26-005223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/f8k_080526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer